Three Years After US Filing, Biocon’s Bevacizumab Remains Out Of Reach

Indian Firm Has Received CRL From FDA, Must Resolve Facility Observations

Following launches in other key developed markets, Biocon’s plans to break into the US bevacizumab market continue to be frustrated, with further bad news from the US Food and Drug Administration.

• Source: Shutterstock

Biocon shelled out billions to take control of the biosimilar joint venture it previously operated with Viatris, but deficiencies observed at several of its key manufacturing facilities continue to hold up US Food and Drug Administration approvals, dwindling further immediate returns on its investment.

In the latest of the company’s frustrations, Biocon has received a complete response letter from the agency rejecting approval for...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Biosimilars

More from Products

  • For Generics, A Victory Lap – And A Warning – On Drug Shortages

    Avoiding disaster at the beginning of the pandemic and offering a pro-active supply chain blueprint should position the generics industry well for an onshoring debate in Congress, but a look back at March 2020 is a reminder that even small policy shifts can have a big impact.

  • GB-Free-Company-The Secret to Walking More: It’s Not Counting Steps

    We’ve all been told that walking 10,000 steps a day is the magic number for better health. But what if the real secret to walking more isn’t about counting steps at all? In this article, we explore how focusing on motivation, environment, and mindset can help you build a walking habit that lasts.

  • Biocon And Teva Sign Up To Biosimilars Forum

    Teva and Biocon Biologics have become the latest firms to sign up to the Biosimilars Forum industry association in the US.